About
Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease.
It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Hemab Therapeutics Holdings, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:COAG
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Analyst Estimates
Street consensus and price targets
Risk Metrics
Volatility versus the market
Earnings Calendar
Upcoming and recent earnings
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | $27.70 | $29.44 | $27.29 | $28.50 | $28.50 | +0.80 | 123,700 |
| 2026-05-28 | $29.26 | $29.89 | $27.60 | $28.00 | $28.00 | -1.26 | 133,000 |
| 2026-05-27 | $28.00 | $30.00 | $27.66 | $28.60 | $28.60 | +0.60 | 147,900 |
| 2026-05-26 | $26.75 | $28.00 | $26.75 | $27.84 | $27.84 | +1.09 | 270,900 |
| 2026-05-22 | $26.30 | $27.04 | $25.21 | $25.89 | $25.89 | -0.41 | 135,200 |
| 2026-05-21 | $26.07 | $27.81 | $25.40 | $26.30 | $26.30 | +0.23 | 193,400 |
| 2026-05-20 | $24.21 | $26.50 | $24.21 | $26.47 | $26.47 | +2.26 | 161,800 |
| 2026-05-19 | $27.15 | $27.43 | $24.60 | $25.44 | $25.44 | -1.71 | 132,600 |
| 2026-05-18 | $27.62 | $27.94 | $25.42 | $27.15 | $27.15 | -0.47 | 151,200 |
| 2026-05-15 | $28.36 | $29.22 | $27.11 | $28.07 | $28.07 | -0.29 | 118,300 |
| 2026-05-14 | $28.43 | $29.31 | $27.30 | $28.37 | $28.37 | -0.06 | 157,600 |
| 2026-05-13 | $26.00 | $28.65 | $25.40 | $28.56 | $28.56 | +2.56 | 209,700 |
| 2026-05-12 | $24.63 | $26.38 | $24.53 | $25.90 | $25.90 | +1.27 | 142,700 |
| 2026-05-11 | $25.10 | $25.31 | $23.00 | $25.00 | $25.00 | -0.10 | 239,300 |
| 2026-05-08 | $25.74 | $26.59 | $24.55 | $25.12 | $25.12 | -0.62 | 207,100 |
| 2026-05-07 | $24.96 | $26.00 | $23.76 | $25.74 | $25.74 | +0.78 | 202,100 |
| 2026-05-06 | $25.25 | $25.98 | $23.48 | $25.01 | $25.01 | -0.24 | 569,600 |
| 2026-05-05 | $23.81 | $25.50 | $23.81 | $25.00 | $25.00 | +1.19 | 461,200 |
| 2026-05-04 | $30.87 | $32.00 | $24.94 | $25.34 | $25.34 | -5.53 | 579,000 |
| 2026-05-01 | $27.00 | $36.61 | $27.00 | $34.00 | $34.00 | +7.00 | 4,113,600 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 10-Q | May 21, 2026 | Quarterly Report |
| 8-K | May 21, 2026 | Current Report |
| SCHEDULE 13G | May 11, 2026 | Filing |
| SCHEDULE 13D | May 11, 2026 | Filing |
| 8-K | May 11, 2026 | Current Report |
| SCHEDULE 13G | May 8, 2026 | Filing |
| 8-K | May 4, 2026 | Current Report |
| S-8 | May 4, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | May 1, 2026 | Prospectus |
| EFFECT | Apr 30, 2026 | Notice of Effectiveness |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Benny Sørensen, M.D., Ph.D
President and Chief Executive Officer, Director
Mads Behrndt, M.Sc
Chief Financial Officer and General Manager
Catherine Madigan, M.D
Chief Medical Officer
Ananthram Murthy, Ph.D., M.Sc.
Chief Operating Officer
John Maraganore, Ph.D.
Chair of the Board of Directors
Linda Bain
Director
Laura Tadvalkar, Ph.D.
Director
Akshay Vaishnaw, M.D., Ph.D
Director
